Navigation Links
PI presents safety results in Neuralstem ALS Stem Cell Trial
Date:4/12/2011

s. All adverse events were resolved. In the group of ambulatory patients, all three remain ambulatory and experienced no serious adverse events secondary to surgery.

"It has been 15-to-4 months since the first nine patients have received the cells," said Karl Johe, Ph.D., Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "There have been no adverse reactions possibly or probably or definitely related to the cells. This indicates that the trial is proceeding as smoothly as can be hoped for. It is designed for transplantation to progress up to the cervical region of spinal cord as safety is demonstrated in the lumbar region," Dr. Johe continued. "With SMB and FDA review of the safety data from the 12 patients due to be completed in the next month, we hope to begin transplanting ALS patients in the cervical region this summer."

"This is significant and, we believe, compelling safety data," said Richard Garr president and CEO of Neuralstem. "It represents the first safety results from the world's first ALS neural stem cell trial, as well as the first data from Neuralstem's ongoing clinical programs. We believe it also validates our proprietary Spinal Injection Platform for the safe intraspinal delivery of our cells. We remain deeply indebted to the patients and their families who are participating in the study."

About the Study

Safety results were presented on nine patients in an ongoing Phase I study to evaluate the safety of Neuralstem's spinal cord stem cells (HSSC's), as well as the transplantation technique, in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).

Of these nine patients, the first six (Cohort A) were all non-ambulatory with permanent paralysis. The first of these was treated on January 20, 2010. Successive surgeries have followed at the rate of one every one-to-two months. The first three patients (Cohort A1) were treated with five unilater
'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Alfred B. Knight, M.D., Scott & White Healthcare, presents at 8th Annual World Health Care Congress
2. Cancer surgery society presents top honor to Kimberly Duchossois
3. Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting
4. John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
5. Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting
6. AAPS presents awards to exemplary researchers
7. Governor presents UH researcher with grant for cardiac device
8. Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting
9. APA presents latest research on same-sex marriage at annual convention in San Diego
10. AOSSM presents prestigious research awards at annual meeting
11. Pfizer Hemophilia presents new data at the World Federation of Hemophilia 2010 Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... March 28, 2015 The "Petrick ... of sustainable health. After 18 years of research and ... professional UFC contenders, Dr. Jon Petrick is excited to ... Just some of the immediate benefits of this radical ... increased levels of strength of the immune system, faster ...
(Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
(Date:3/27/2015)... In her mid-forties and with a lifelong ... Monica K. arrived at JET Uniform & Supply ... and scared. The owners and staff at JET, which had ... to offer jobs to challenged residents like Monica, were patient. ... to begin with the end in mind,” says Stephen Milaney, ...
(Date:3/27/2015)... Kansas City, Mo (PRWEB) March 27, 2015 ... common complications for patients undergoing percutaneous coronary intervention ... Ironically, studies have observed a “risk-treatment paradox,” in ... to gain from treatment are treated less often ... , Researchers at Saint Luke’s Mid America Heart ...
(Date:3/27/2015)... 27, 2015 Ticket Down is a reputable source ... 2015. After a phenomenal and highly successful live tour last ... going out on tour again in 2015 and they will be ... on April 29th in New York City at the cozy Beacon ... Theatre on May 10th. , Fans of the hit show can ...
Breaking Medicine News(10 mins):Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical ... for the treatment of human viral,and other infectious ... quarter and year ended December 31, 2007. At ... securities totaled,$112.0 million., Significant ...
... March 6, 2008 A study released this ... Healthcare System in California shows that non-polypoid colorectal neoplasms ... than previously thought and may have a greater association ... commonly diagnosed colorectal polyp. The study appears in the ...
... of nursing would,help address the severe nurse faculty ... WASHINGTON, March 6 Today, the American,Association ... Durbin,(D-IL) for introducing the Troops to Nurse Teachers ... when the military and civilian healthcare systems have,been ...
... A study released,this week from researchers at ... shows that non-polypoid colorectal neoplasms or flat,colon lesions, ... and may,have a greater association with cancer compared ... polyp. The study appears in the,March 5 issue ...
... DALLAS, March 6 State Medicaid programs ... innovative,initiative of Affiliated Computer Services, Inc. (NYSE: ... ACS, healthcare clients avoid costly,manual recovery of drug ... enables pharmacies to immediately identify pharmacy,benefit coverage at ...
... offers hope of new diabetes treatments , , THURSDAY, ... levels disable the molecular switch that normally turns off ... insulin levels, a California study finds. , This ... the "sugar-off" switch (CRTC2) may help lower glucose levels ...
Cached Medicine News:Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 7Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 8Health News:Colonoscopy used to identify and remove flat colon lesions 2Health News:AACN Applauds Senator Richard Durbin for Introducing the Troops to Nurse Teachers Act of 2008 2Health News:AACN Applauds Senator Richard Durbin for Introducing the Troops to Nurse Teachers Act of 2008 3Health News:Colonoscopy Used to Identify and Remove Flat Colon Lesions: Flat Colon Lesions More Common and More Likely to Be Cancer According to JAMA Study 2Health News:Colonoscopy Used to Identify and Remove Flat Colon Lesions: Flat Colon Lesions More Common and More Likely to Be Cancer According to JAMA Study 3Health News:Colonoscopy Used to Identify and Remove Flat Colon Lesions: Flat Colon Lesions More Common and More Likely to Be Cancer According to JAMA Study 4Health News:ACS Launches Medicaid Cost Savings Initiative 2Health News:ACS Launches Medicaid Cost Savings Initiative 3Health News:Constant High Blood Sugar Disables Insulin 'Off' Switch 2
(Date:3/27/2015)... March 27, 2015  RXi Pharmaceuticals Corporation ... LLC, today announced that they have entered ... novel and proprietary sd-rxRNA® technology for use ... collaboration has the potential to result in ... treatments that could be a significant step ...
(Date:3/27/2015)... , March 27, 2015  WebMD ... leading source of health information, today announced ... new National Action Plan for Combating ... Obama emphasized the urgency and importance of ... national and global health.    The ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
Breaking Medicine Technology:RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
... HAMILTON, Bermuda , April 30 Celtic Pharmaceutical Holdings L.P. ... pharmaceutical industries, announced today the enrolment of the first patient into its ... treatment of onychomycosis (also known as a fungal nail infection).   , ... This Phase III trial is ...
... , April 29 Abraxis BioScience initially ... the former ICN/Valient Pharmaceutical building in Costa Mesa, ... foot building. The "due diligence report" revealed an array ... occupying the building, and once the building purchase was ...
Cached Medicine Technology:Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 2Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 3Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 4LCS Constructors, Inc. Completes First Major Phase of Abraxis BioScience Project 2
... including aspiration holes and additional electrode ... requiring precise dissection with decreased risk ... demands. ,Flexible design options allow ... electrodes and multiple tip designs. Optimize ...
... Enhanced features including aspiration holes and ... laparoscopic procedures requiring precise dissection with ... increased suction demands. ,Flexible design ... and nonretractable electrodes and multiple tip ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: